Flavonoids activate wild-type p53

被引:0
|
作者
Plaumann, B
Fritsche, M
Rimpler, H
Brandner, G
Hess, RD
机构
[1] UNIV FREIBURG, INST MED MIKROBIOL & HYG, ABT VIROL, D-79104 FREIBURG, GERMANY
[2] INST EXPT KREBSFORSCH, KLIN TUMORBIOL, D-79106 FREIBURG, GERMANY
[3] UNIV FREIBURG, INST PHARMAZEUT BIOL, D-79104 FREIBURG, GERMANY
关键词
flavonoids; p53; cell cycle; G2M; apoptosis; DNA damage;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Flavonoids are diphenyl propanoids widely distributed in edible plants. They play a dual role in mutagenesis and carcinogenesis. Some of them act as anticarcinogens or inhibit the growth of tumour cells, whereas others act as cocarcinogens, are mutagenic or able to induce DNA damage. To further elucidate this dual role, we investigated the influence of apigenin, luteolin and quercetin on the tumour suppressor protein p53, regarding p53 accumulation, cell cycle arrest, apoptosis, and biological activity. We found that incubation of the non-tumour cell line C3H10T1/2CL8 with these flavonoids resulted in induction of p53 accumulation and apoptosis. Apoptosis occurred out of the G(2)/M phase of the cell cycle, The G(2)/M arrest seems to be p53-dependent as it did not occur in p53 knockout fibroblasts which further supports the recent finding that p53 is involved in the G(2)/M checkpoint control. Differences between the flavonoids tested concerned p53 accumulation kinetics as well as the biological activity of accumulated p53 and might be due to different modes of flavonoid action. These data suggest that both aspects of flavonoid effects, i.e. inhibition of tumour growth through cell cycle arrest and induction of apoptosis, are functionally related to p53.
引用
收藏
页码:1605 / 1614
页数:10
相关论文
共 50 条
  • [1] COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION
    MILNER, J
    MEDCALF, EA
    [J]. CELL, 1991, 65 (05) : 765 - 774
  • [2] Activities of wild-type and mutant p53
    Vousden, Karen H.
    [J]. CANCER RESEARCH, 2013, 73
  • [3] ACCUMULATION OF WILD-TYPE P53 IN MENINGIOMAS
    ELLISON, DW
    LUNEC, J
    GALLAGHER, PJ
    STEART, PV
    JAROS, E
    GATTER, KC
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1995, 21 (02) : 136 - 142
  • [4] Contribution of the p53 pathway in cancers that carry wild-type p53
    Ohki, Rieko
    [J]. CANCER SCIENCE, 2022, 113 : 1232 - 1232
  • [5] Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy
    Allende-Vega, Nerea
    Saville, Mark K.
    [J]. SEMINARS IN CANCER BIOLOGY, 2010, 20 (01) : 29 - 39
  • [6] TUMOR SUPPRESSOR P53 - ANALYSIS OF WILD-TYPE AND MUTANT P53 COMPLEXES
    MILNER, J
    MEDCALF, EA
    COOK, AC
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (01) : 12 - 19
  • [7] WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO
    FARMER, G
    BARGONETTI, J
    ZHU, H
    FRIEDMAN, P
    PRYWES, R
    PRIVES, C
    [J]. NATURE, 1992, 358 (6381) : 83 - 86
  • [8] Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53
    M Szybka
    I Zawlik
    D Kulczycka
    E Golanska
    E Jesien
    D Kupnicka
    R Stawski
    S Piaskowski
    E Bieniek
    M Zakrzewska
    R Kordek
    P P Liberski
    P Rieske
    [J]. British Journal of Cancer, 2008, 98 : 1431 - 1433
  • [9] INACTIVE P53 MUTANTS MAY ENHANCE THE TRANSCRIPTIONAL ACTIVITY OF WILD-TYPE P53
    ZHANG, W
    SHAY, JW
    DEISSEROTH, A
    [J]. CANCER RESEARCH, 1993, 53 (20) : 4772 - 4775
  • [10] Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators
    Roemer, K
    [J]. BIOLOGICAL CHEMISTRY, 1999, 380 (7-8) : 879 - 887